[go: up one dir, main page]

AR003112A1 - Un metodo para controlar la expresion de un gen estructural en una celula, construcciones de adn para uso en dicho metodo y capaz de alterar la expresionde un gen codificante de trombopoyetina, adnasa o interferon beta, molecula de adn aislado, celulas homologamente recombinantes, metodos para producir dichas - Google Patents

Un metodo para controlar la expresion de un gen estructural en una celula, construcciones de adn para uso en dicho metodo y capaz de alterar la expresionde un gen codificante de trombopoyetina, adnasa o interferon beta, molecula de adn aislado, celulas homologamente recombinantes, metodos para producir dichas

Info

Publication number
AR003112A1
AR003112A1 ARP960101759A AR10175996A AR003112A1 AR 003112 A1 AR003112 A1 AR 003112A1 AR P960101759 A ARP960101759 A AR P960101759A AR 10175996 A AR10175996 A AR 10175996A AR 003112 A1 AR003112 A1 AR 003112A1
Authority
AR
Argentina
Prior art keywords
expression
gene
dna
cell
structural gene
Prior art date
Application number
ARP960101759A
Other languages
English (en)
Original Assignee
Docampo Palacios Maite L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Docampo Palacios Maite L filed Critical Docampo Palacios Maite L
Publication of AR003112A1 publication Critical patent/AR003112A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/524—Thrombopoietin, i.e. C-MPL ligand
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Se describe un método para controlar la expresión de un gen estructural en una célula que comprende las etapas de:a) proporcionar una construcción de ADNque comprende una secuencia de inserción dirigida, una secuencia reguladora y un sitiodonador de empalme;b)establecer una secuencia de ADN interventor entrela secuencia reguladora y el gen estructural por inserción de la construcción en la célula por recombinación homóloga en una posición preseleccionada conrespecto al genestructural para producir una célula homólogamente recombinante en que la construcción insertada adopta una configuración por la que lasecuencia reguladora se separa del gen estructural por una longitud preseleccionada de ADNinterventor,estando colocado el sitio donador de empalmede manera que se separa ARN cognaticio del ADN interventor durante el empalme post-transcripcional del transcripto primario; y c) controlar la expresión delgen estructural por variación de lalongitud de ADN interventor seleccionado en la etapa (b). Las construcciones de inserción dirigida comprenden al menos: a)una secuencia dirigida;b) una secuencia reguladora; c) un exón; y d) un sitio donador de empalme. Dichas construcciones quepueden experimentar recombinac iónhomóloga con secuencias celulares endógenas para generar un gen novedoso, se introducen en células para producir células homólogamente recombinantes. Lascélulas dan como resultado la producción de uno cualquierade trombopoyetina, ADNasa I o interferón Beta. La invención se refiere además a métodos deproducción de preparaciones farmacéuticamente útiles que contienen trombopoyetina, ADNasa (I) o inteferón Beta a partir de célulashomólogamenterecombinantes y métodos de terapi a.
ARP960101759A 1995-03-17 1996-03-15 Un metodo para controlar la expresion de un gen estructural en una celula, construcciones de adn para uso en dicho metodo y capaz de alterar la expresionde un gen codificante de trombopoyetina, adnasa o interferon beta, molecula de adn aislado, celulas homologamente recombinantes, metodos para producir dichas AR003112A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/406,030 US6270989B1 (en) 1991-11-05 1995-03-17 Protein production and delivery

Publications (1)

Publication Number Publication Date
AR003112A1 true AR003112A1 (es) 1998-07-08

Family

ID=23606267

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP960101759A AR003112A1 (es) 1995-03-17 1996-03-15 Un metodo para controlar la expresion de un gen estructural en una celula, construcciones de adn para uso en dicho metodo y capaz de alterar la expresionde un gen codificante de trombopoyetina, adnasa o interferon beta, molecula de adn aislado, celulas homologamente recombinantes, metodos para producir dichas

Country Status (10)

Country Link
US (1) US6270989B1 (es)
EP (1) EP0815232A1 (es)
JP (1) JPH11502122A (es)
AR (1) AR003112A1 (es)
AU (1) AU725832B2 (es)
CA (1) CA2215618A1 (es)
IL (1) IL117468A0 (es)
MY (1) MY134810A (es)
WO (1) WO1996029411A1 (es)
ZA (1) ZA962116B (es)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7597886B2 (en) 1994-11-07 2009-10-06 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
US7888466B2 (en) 1996-01-11 2011-02-15 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68
DE19743497A1 (de) 1996-10-01 1998-08-20 Geron Corp Katalytische Untereinheit menschlicher Telomerase
US6855545B1 (en) 1996-10-04 2005-02-15 Lexicon Genetics Inc. Indexed library of cells containing genomic modifications and methods of making and utilizing the same
US7332338B2 (en) 1996-10-04 2008-02-19 Lexicon Pharmaceuticals, Inc. Vectors for making genomic modifications
US6642360B2 (en) * 1997-12-03 2003-11-04 Genentech, Inc. Secreted polypeptides that stimulate release of proteoglycans from cartilage
US5989909A (en) * 1997-09-26 1999-11-23 Millennium Biotherapeutics, Inc. Huchordin and uses thereof
GB9715064D0 (en) * 1997-07-17 1997-09-24 Ppl Therapeutics Scotland Ltd Protein expression
PT1000154E (pt) 1997-07-23 2007-03-30 Roche Diagnostics Gmbh Identificação de linhas celulares humanas para a produção de proteínas humanas por activação endógena de genes
BRPI9811031B8 (pt) * 1997-07-23 2021-07-06 Roche Diagnostics Gmbh processo para preparar uma célula produtora de epo humana, processo para preparar epo humana, construção de dna para ativação de gene de epo endógeno, bem como plasmìdio.
ATE354654T1 (de) 1997-07-23 2007-03-15 Roche Diagnostics Gmbh Identifizierung humaner zellinien zur produktion humaner proteine durch endogene genaktivierung
BR9811531A (pt) * 1997-07-23 2000-08-22 Roche Diagnostics Gmbh Preparação de proteìnas mutadas humanas em células humanas por meio de recombinação homóloga
KR100641969B1 (ko) 1997-07-23 2006-11-06 로셰 디아그노스틱스 게엠베하 내인성 유전자 활성화에 의한 에리트로포이에틴의제조방법
US6740503B1 (en) 1997-09-26 2004-05-25 Athersys, Inc. Compositions and methods for non-targeted activation of endogenous genes
JP5377806B2 (ja) * 1997-09-26 2013-12-25 アサーシス，インコーポレイテッド ベクター構築物の細胞ｄｎａとの非相同組換えによる内因性遺伝子の発現
US6897066B1 (en) 1997-09-26 2005-05-24 Athersys, Inc. Compositions and methods for non-targeted activation of endogenous genes
CN1174993C (zh) 1997-11-03 2004-11-10 人体基因组科学有限公司 Vegi,一种血管发生和肿瘤生长的抑制剂
AU757930B2 (en) * 1997-12-01 2003-03-13 Roche Diagnostics Gmbh Optimization of cells for endogenous gene activation
WO1999044625A1 (en) 1998-03-03 1999-09-10 John Hopkins University Smallpox inhibitor of complement enzymes (spice) protein and methods of inhibiting complement activation
WO1999047538A1 (en) 1998-03-19 1999-09-23 Human Genome Sciences, Inc. Cytokine receptor common gamma chain like
US6436707B1 (en) * 1998-03-27 2002-08-20 Lexicon Genetics Incorporated Vectors for gene mutagenesis and gene discovery
CA2343979C (en) 1998-09-21 2011-11-15 Schering Corporation Human interleukin-b50, therapeutic uses
EP0997476A3 (en) 1998-09-25 2000-07-19 Schering-Plough Antibodies to a mammalian Langerhans cell antigen and their uses
CA2364267A1 (en) * 1999-02-19 2000-08-24 Athersys, Inc. Compositions and methods for non-targeted activation of endogenous genes
AU3501700A (en) 1999-02-26 2000-09-14 Human Genome Sciences, Inc. Human endokine alpha and methods of use
US20050129669A1 (en) * 1999-06-21 2005-06-16 Transkaryotic Therapies, Inc., A Massachusetts Corporation DNA construct for effecting homologous recombination and uses thereof
ES2330406T3 (es) 1999-07-30 2009-12-10 Schering Corporation Citocinas de mamifero; reactivos relacionados.
EP3184637A1 (en) 1999-09-09 2017-06-28 Merck Sharp & Dohme Corp. Mammalian interleukin-12 p40 and interleukin b30 complexes, antibodies, uses in pharmaceutical compositions
US6951839B1 (en) 1999-11-30 2005-10-04 Curis, Inc. Methods and compositions for regulating lymphocyte activity
US8168178B2 (en) 1999-11-30 2012-05-01 Curis, Inc. Methods and compositions for regulating lymphocyte activity
WO2001042442A2 (en) 1999-12-10 2001-06-14 Cytos Biotechnology Ag Activation of endogenous genes by genomic introduction of a replicon
TW201006846A (en) 2000-03-07 2010-02-16 Senomyx Inc T1R taste receptor and genes encidung same
EP1728862A1 (en) 2000-03-16 2006-12-06 Genetica, Inc. Methods and compositions for RNA interference
US20030084471A1 (en) 2000-03-16 2003-05-01 David Beach Methods and compositions for RNA interference
EP1803730A1 (en) 2000-04-12 2007-07-04 Human Genome Sciences, Inc. Albumin fusion proteins
EP1294949A4 (en) 2000-06-15 2004-08-25 Human Genome Sciences Inc HUMAN TUMORNESCROSE FACTOR DELTA AND EPSILON
GB0018876D0 (en) * 2000-08-01 2000-09-20 Applied Research Systems Method of producing polypeptides
US7138262B1 (en) * 2000-08-18 2006-11-21 Shire Human Genetic Therapies, Inc. High mannose proteins and methods of making high mannose proteins
AU2001288478B2 (en) 2000-08-25 2006-11-02 Basf Plant Science Gmbh Plant polynucleotides encoding prenyl proteases
JP2004509617A (ja) 2000-09-08 2004-04-02 シェーリング　コーポレイション 哺乳動物遺伝子；関連試薬および方法
TW201022287A (en) 2001-01-03 2010-06-16 Senomyx Inc T1R taste receptors and genes encoding same
CA2437811A1 (en) 2001-02-09 2002-08-22 Human Genome Sciences, Inc. Human g-protein chemokine receptor (ccr5) hdgnr10
US7883856B2 (en) 2001-04-05 2011-02-08 Senomyx Inc. Identification of bitter ligands that specifically activate human T2R receptors and related assays for identifying human bitter taste modulators
WO2002083704A1 (en) 2001-04-13 2002-10-24 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US7629309B2 (en) * 2002-05-29 2009-12-08 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US20040005309A1 (en) * 2002-05-29 2004-01-08 Symbiontics, Inc. Targeted therapeutic proteins
WO2002087510A2 (en) * 2001-04-30 2002-11-07 Symbiontics, Inc. Subcellular targeting of therapeutic proteins
US7560424B2 (en) 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
WO2003001876A2 (en) 2001-06-26 2003-01-09 Senomyx, Inc. T1r hetero-oligomeric taste receptors and cell lines that express said receptors and use thereof for identification of taste compounds
IL159640A0 (en) 2001-07-10 2004-06-01 Senomyx Inc Use of specific t2r taste receptors to identify compounds that block bitter taste
US6867189B2 (en) 2001-07-26 2005-03-15 Genset S.A. Use of adipsin/complement factor D in the treatment of metabolic related disorders
US20030082511A1 (en) * 2001-09-25 2003-05-01 Brown Steven J. Identification of modulatory molecules using inducible promoters
US20030072761A1 (en) * 2001-10-16 2003-04-17 Lebowitz Jonathan Methods and compositions for targeting proteins across the blood brain barrier
US20080194481A1 (en) 2001-12-21 2008-08-14 Human Genome Sciences, Inc. Albumin Fusion Proteins
US7255874B1 (en) 2001-12-21 2007-08-14 Closure Medical Corporation Biocompatible polymers and adhesives: compositions, methods of making and uses related thereto
EP2277910A1 (en) 2001-12-21 2011-01-26 Human Genome Sciences, Inc. Albumin fusion proteins
WO2003066085A1 (en) 2002-02-07 2003-08-14 Delta Biotechnology Limited Albumin-fused anti-angiogenesis peptides
EP1503788B1 (en) 2002-04-25 2011-06-29 Shire Human Genetic Therapies, Inc. Treatment of alpha-galactosidase a deficiency
AU2003254016A1 (en) 2002-07-19 2004-02-09 Catholic Healthcare West Methods and compositions relating to chimeric nicotinic receptor subunits
US20050048041A1 (en) * 2003-01-13 2005-03-03 Rao Mahendra S. Persistent expression of candidate molecule in proliferating stem and progenitor cells for delivery of therapeutic products
CA2513226A1 (en) * 2003-01-13 2004-07-29 Mahendra S. Rao Persistent expression of candidate molecule in proliferating stem and progenitor cells for delivery of therapeutic products
JP2006518997A (ja) 2003-01-21 2006-08-24 ブリストル−マイヤーズ　スクイブ　カンパニー 新規アシルコエンザイムａ：モノアシルグリセロールアシルトランスフェラーゼ−３（ｍｇａｔ３）をコードするポリヌクレオチドおよびその用途
CN101444621B (zh) 2003-02-11 2013-11-20 夏尔人类遗传性治疗公司 使用甲酰-甘氨酸生成酶(fge)对多种硫酸酯酶缺乏症和其它病症进行诊断和治疗
US8088737B2 (en) 2003-04-04 2012-01-03 Incyte Corporation Compositions, methods and kits relating to Her-2 cleavage
US7205148B2 (en) * 2003-06-11 2007-04-17 Regeneron Pharmaceuticals, Inc. Genome mutation by intron insertion into an embryonic stem cell genome
AU2004263871B2 (en) 2003-08-06 2011-07-14 Senomyx, Inc. T1R hetero-oligomeric taste receptors, cell lines that express said receptors, and taste compounds
US7998104B2 (en) * 2003-11-21 2011-08-16 Silk Road Medical, Inc. Method and apparatus for treating a carotid artery
CA2553955C (en) * 2004-02-10 2012-08-28 Zystor Therapeutics, Inc. Acid alpha-glucosidase and fragments thereof
US7482124B2 (en) 2005-07-08 2009-01-27 Bristol-Myers Squibb Company Method of identifying a PPARgamma-agonist compound having a decreased likelihood of inducing dose-dependent peripheral edema
KR20080074120A (ko) 2005-10-13 2008-08-12 휴먼 게놈 사이언시즈, 인코포레이티드 자가항체 양성 질환 환자의 치료에 유용한 방법 및 조성물
JP5342878B2 (ja) 2005-10-20 2013-11-13 セノミクス・インコーポレーテッド キメラヒト甘味‐旨味および旨味‐甘味味覚受容体
JP5364382B2 (ja) 2006-02-07 2013-12-11 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド 遊離チオール部分を有するタンパク質の安定化された組成物
TWI425917B (zh) 2006-04-21 2014-02-11 Senomyx Inc 包含高度鮮味風味劑之可食用組合物及其製造方法
US7572618B2 (en) 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
US9505823B2 (en) 2006-08-07 2016-11-29 TEV A Biopharmaceuticals USA, Inc. Albumin-insulin fusion proteins
JP2010509344A (ja) * 2006-11-13 2010-03-25 ザイストール セラピューティクス， インコーポレイテッド ポンペ病を治療するための方法
ES2389618T3 (es) 2007-04-16 2012-10-29 Momenta Pharmaceuticals, Inc. Productos de glucoproteínas definidas y métodos relacionados
AU2008289485B2 (en) 2007-08-21 2014-08-14 Senomyx, Inc. Human T2R bitterness receptors and uses thereof
PT2279210T (pt) 2008-05-07 2017-07-10 Biomarin Pharm Inc Péptidos de direcionamento lisossomal e suas utilizações
ES2758827T3 (es) 2009-06-17 2020-05-06 Biomarin Pharm Inc Formulaciones para enzimas lisosómicas
MX344786B (es) 2009-07-28 2017-01-06 Shire Human Genetic Therapies Composiciones y metodos para tratar enfermedad de gaucher.
US8883739B2 (en) 2010-01-19 2014-11-11 The Trustees Of Columbia University In The City Of New York Osteocalcin as a treatment for male reproductive disorders
US9453847B2 (en) 2010-07-19 2016-09-27 Shire Human Genetic Therapies, Inc. Mannose receptor C type 1 (MRC1) codon optimized cell line and uses thereof
CN103732628B (zh) 2011-03-03 2017-06-23 酵活有限公司 多价杂多聚体骨架设计和构建体
US9623090B2 (en) 2012-03-02 2017-04-18 Shire Human Genetic Therapies, Inc. Compositions and methods for treating type III gaucher disease
CN104768571B (zh) 2012-07-13 2018-11-09 酵活有限公司 多价异多聚体支架设计和构建体
US10052364B2 (en) 2013-03-15 2018-08-21 The Trustees Of Columbia University In The City Of New York Osteocalcin as a treatment for cognitive disorders
WO2014182970A1 (en) 2013-05-08 2014-11-13 Zymeworks Inc. Bispecific her2 and her3 antigen binding constructs
EP3226889A4 (en) 2014-11-19 2018-11-21 The Trustees of Columbia University in the City of New York Osteocalcin as a treatment for frailty associated with aging
CA2874083C (en) 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
US10967073B2 (en) 2015-05-07 2021-04-06 The Mclean Hospital Corporation Glucocerebrosidase gene therapy for Parkinson's disease
EP3351263A1 (en) 2017-01-20 2018-07-25 Universitätsklinikum Hamburg-Eppendorf Pharmaceutical preparation for treating or preventing tissue adhesion
AU2017398101B2 (en) 2017-02-07 2025-02-06 Janssen Biotech, Inc. Anti-TNF antibodies, compositions, and methods for the treatment of active Ankylosing Spondylitis
IL317968A (en) * 2017-08-18 2025-02-01 Neutrolis Inc Engineered deoxyribonuclease enzymes and their use in medicine
US10988746B2 (en) 2018-10-08 2021-04-27 Neutrolis, Inc. Manufacturing and engineering of DNASE enzymes for therapy
JP2022504400A (ja) 2018-10-08 2022-01-13 ニュートロリス インコーポレイテッド 製造及び治療のためのｄｎａｓｅ酵素の操作
SG11202103334YA (en) 2018-10-26 2021-05-28 Hoffmann La Roche Multispecific antibody screening method using recombinase mediated cassette exchange
EP4036232A4 (en) * 2019-09-20 2023-01-11 Ractigen Therapeutics Nucleic acid molecule for treating immune thrombocytopenia and application thereof

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4497796A (en) 1980-03-26 1985-02-05 The Regents Of The University Of California Gene transfer in intact mammals
EP0038765B1 (fr) 1980-04-22 1987-09-02 Institut Pasteur Vaccin contre l'hépatite virale B, procédé et cellules eucaryotes transformées pour la production de ce vaccin
US4751348A (en) * 1983-07-16 1988-06-14 Cold Spring Harbor Laboratory Nicotiana plants with both altered polyamine levels and flower structures and method for obtaining these plants
KR850004274A (ko) 1983-12-13 1985-07-11 원본미기재 에리트로포이에틴의 제조방법
US4703008A (en) 1983-12-13 1987-10-27 Kiren-Amgen, Inc. DNA sequences encoding erythropoietin
NZ210501A (en) 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
US4680174A (en) 1984-05-24 1987-07-14 Damon Biotech, Inc. Induction of immune response by immunization with encapsulated antigen-producing cells
CA1215922A (en) 1984-05-25 1986-12-30 Connaught Laboratories Limited Microencapsulation of living tissue and cells
ATE68013T1 (de) 1985-07-05 1991-10-15 Whitehead Biomedical Inst Expression von fremdem genetischem material in epithelzellen.
ATE145558T1 (de) 1987-05-01 1996-12-15 Gen Hospital Corp Transkaryotische einpflanzung
GB8718779D0 (en) 1987-08-07 1987-09-16 Grosveld F G Dna sequence & expression vector
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5171674A (en) * 1988-07-13 1992-12-15 Brigham And Women's Hospital Polynucleotides that encode the human proteoglycan peptide core of the effector cells of the immune response
US5082670A (en) 1988-12-15 1992-01-21 The Regents Of The University Of California Method of grafting genetically modified cells to treat defects, disease or damage or the central nervous system
US5236838A (en) * 1988-12-23 1993-08-17 Genzyme Corporation Enzymatically active recombinant glucocerebrosidase
FR2646438B1 (fr) 1989-03-20 2007-11-02 Pasteur Institut Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration
AU635844B2 (en) 1989-11-06 1993-04-01 Cell Genesys, Inc. Production of proteins using homologous recombination
DK0505500T3 (da) 1989-12-22 1997-08-25 Applied Research Systems Modificering af endogen genekspression med regulatorisk element ved hjælp af homolog rekombination
US5272071A (en) 1989-12-22 1993-12-21 Applied Research Systems Ars Holding N.V. Method for the modification of the expression characteristics of an endogenous gene of a given cell line
FI914947A7 (fi) 1990-02-22 1991-10-21 Gene Pharming Europe B V Polypeptidien parantunut ilmentyminen
IT1241123B (it) 1990-04-19 1993-12-29 Consiglio Nazionale Ricerche Cellule umane per l'elevata espressione di geni inseriti in dna ricombinanti episomiali,loro preparazione e loro impiego
JPH05507853A (ja) 1990-06-12 1993-11-11 ベイラー・カレッジ・オブ・メディシン 動物細胞および植物細胞における相同的組換え法
US5356804A (en) * 1990-10-24 1994-10-18 Mount Sinai School Of Medicine Of The City Of New York Cloning and expression of biologically active human α-galactosidase A
AU669484B2 (en) * 1991-07-31 1996-06-13 Peri Development Applications (1985) Ltd Transgenic protein production
AU2515992A (en) 1991-08-20 1993-03-16 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
DE4128319A1 (de) * 1991-08-27 1993-03-04 Bioferon Biochem Substanz Neues rekombinantes human-ifn-beta, verfahren zu dessen herstellung und dieses enthaltende pharmazeutische zubereitungen
AU710255B2 (en) * 1991-11-05 1999-09-16 Transkaryotic Therapies, Inc. Transfection of vertebrate cells e.g. by homologous recombination
PT101031B (pt) 1991-11-05 2002-07-31 Transkaryotic Therapies Inc Processo para o fornecimento de proteinas por terapia genetica
US5641670A (en) * 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
MX9305183A (es) 1992-08-27 1994-05-31 Us Agriculture Intron portatil, molecula de adn genomico viral, virus vivo y vacuna que los contiene y metodo para su obtencion.
DE69312309T2 (de) 1992-11-02 1997-12-18 Genentech Inc Verdichtungsprüfung zur bewertung einer therapie für eine atmungskrankheit
TW402639B (en) 1992-12-03 2000-08-21 Transkaryotic Therapies Inc Protein production and protein delivery
GB2285446B (en) 1994-01-03 1999-07-28 Genentech Inc Thrombopoietin
WO1995021626A1 (en) 1994-02-14 1995-08-17 University Of Washington Methods for stimulating erythropoiesis using thrombopoietin

Also Published As

Publication number Publication date
EP0815232A1 (en) 1998-01-07
AU5362596A (en) 1996-10-08
IL117468A0 (en) 1996-07-23
JPH11502122A (ja) 1999-02-23
MY134810A (en) 2007-12-31
US6270989B1 (en) 2001-08-07
CA2215618A1 (en) 1996-09-26
WO1996029411A1 (en) 1996-09-26
AU725832B2 (en) 2000-10-19
ZA962116B (en) 1996-10-03

Similar Documents

Publication Publication Date Title
AR003112A1 (es) Un metodo para controlar la expresion de un gen estructural en una celula, construcciones de adn para uso en dicho metodo y capaz de alterar la expresionde un gen codificante de trombopoyetina, adnasa o interferon beta, molecula de adn aislado, celulas homologamente recombinantes, metodos para producir dichas
FI964536A7 (fi) DNA-rakenne homologisen rekombinaation suorittamiseksi ja sen käyttöjä
US4332892A (en) Protein synthesis
Padgett et al. Splicing of messenger RNA precursors
ES8602133A1 (es) Un procedimiento para preparar un vector de transferencias de adn
AR005568A1 (es) Moleculas y construcciones de adn para aumentar la expresion de genes foraneos; celulas y plantas transformadas y metodo para producirlas
US4418149A (en) Fused hybrid gene
Hellerman et al. Secretion of human parathyroid hormone from rat pituitary cells infected with a recombinant retrovirus encoding preproparathyroid hormone.
HU195534B (en) Process for preparing polypeptide by bacterial way, by using tryptophan promoter operator
DK0750044T3 (da) DNA-konstruktioner og transfektion af celler dermed til homolog rekombination
WO2002014495B1 (en) Enhanced homologous recombination mediated by lambda recombination proteins
EP1328653A4 (en) HIGHLY EXPRESSABLE GENES
CN112912497B (zh) 工程化长散在元件(line)转座子及其使用方法
ES2116683T3 (es) Gen de la beta-galactosidasa hipertermoestable.
KR880009991A (ko) 항혈액응고작용을 갖는 폴리펩티드
CU22722A1 (es) Sistema de transformación para la expresión de genes heterólogos en la levadura candida utilis
WO1998017814A3 (en) Gene expression and delivery systems and uses
JP7416745B2 (ja) 改変細胞、調製方法、及び構築物
ATE254171T1 (de) Gentherapeutisches verfahren unter verwendung von dna-vektoren ohne selektionsmarker-gen
GR900100012A (el) Μέ?οδος εισαγωγής εξωγενούς DNA σε σωματικά και γεννητικά ζωικά κύτταρα.
CN112626120A (zh) 一种新型基因编辑工具的设计及其使用方法
EE03074B1 (et) Rekombinantsed eukarüootsed rakud, nende saamiseks vajalikud DNA järjestused, meetod eukarüootsete rakkude konstrueerimiseks ja sekreteeritavate valkude ning biomassi tootmismeetod
ES2061524T3 (es) Un vector plasmidico para la expresion en bacillus y empleado para la clonacion del gen estructural que codifica la hormona de crecimiento humana y un metodo para la produccion de la hormona.
GB2039916A (en) Protein synthesis by genetic manipulation
ATE469221T1 (de) Verbesserte stämme von enterobacteiaceae für fermentation

Legal Events

Date Code Title Description
FB Suspension of granting procedure